Nanosphere Health Sciences Inc
CNSX:NSHS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
J
|
Johor Plantations Group Bhd
KLSE:JPG
|
MY |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (10.1), the stock would be worth CA$-0.19 (866% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -1.3 | CA$0.03 |
0%
|
| Industry Average | 10.1 | CA$-0.19 |
-866%
|
| Country Average | 14.4 | CA$-0.27 |
-1 191%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
N
|
Nanosphere Health Sciences Inc
CNSX:NSHS
|
256.9k CAD | -1.3 | 0.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 27.4 | 40.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 16.7 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.9 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 15.6 | 28 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 12.1 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 9.5 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 8.4 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 7.6 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.2B USD | 7.2 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Nanosphere Health Sciences Inc
Glance View
NanoSphere Health Sciences, Inc. is a biotechnology company. The company is headquartered in Greenwood Village, Colorado. The company went IPO on 2005-08-11. The firm is commercializing its disruptive, nanoparticle delivery system platforms for cannabis under the brand Evolve Formulas available in a number of accounts throughout Colorado. Evolve has already launched its NanoSerum product for the recreational and medical cannabis markets in Colorado. NanoSerum is the clinically tested transdermal cannabis product to relieve pain. The firm is owner of NanoSphere Health Sciences LLC which is, a biotechnology firm specializing in the creation of the NanoSphere Delivery System, a platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries.
